Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000883 · ClinicalTrials.gov registry record
Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior
A clinical trial of Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Recruiting
- Registry status
- 10,000
- Enrollment target
- 1
- Study location
NCT01000883: Recruiting study of Breast Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.
NCT01000883 is a study of Breast Cancer that is actively recruiting participants, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 10,000 participants, above the 2,795-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (258% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01000883, a study of Breast Cancer, is actively recruiting participants, sponsored by UNC Lineberger Comprehensive Cancer Center.
- RECRUITING
- Registry status
- 10,000 participants
- Enrollment target
- 1
- Study location
Study Summary
RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tissue and blood samples from women with locally advanced or metastatic breast cancer
Conditions Studied
Interventions
- OTHER biologic sample preservation procedure
- OTHER laboratory biomarker analysis
- PROCEDURE biopsy
Study Locations (1)
North Carolina
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10,000 participants |
| Start Date | 1998-12-01 |
| Est. Completion | 2032-11 |
What NCT01000883 shows while recruiting
NCT01000883 is an observational study that tracks outcomes without assigning an intervention. Its 10,000 participants enrollment target places it among the larger protocols in the corpus, above the 2,795-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (258% higher).
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 3 interventions - of which biologic sample preservation procedure is the first listed.
NCT01000883 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT01000883 about?
NCT01000883 is a clinical study titled "Correlation of Molecular Markers With Response to Therapy and Breast Cancer Behavior". RATIONALE: Studying samples of tumor tissue and blood from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research st...
What is the current status of trial NCT01000883?
This trial is currently recruiting. The enrollment target is 10,000 participants. The study started on 1998-12-01. Estimated completion is 2032-11.
What conditions does trial NCT01000883 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT01000883?
The interventions under investigation include: biologic sample preservation procedure (OTHER), laboratory biomarker analysis (OTHER), biopsy (PROCEDURE).
Who is sponsoring clinical trial NCT01000883?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01000883 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01000883's enrollment target sits among peer trials
10,000 16th of 1224 higher than 1,208 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00160771 · 10,000 participants
Biomechanics/Motion Analysis Laboratory Data Bank
- NCT00896935 · 10,000 participants
Arizona Cancer Center Biospecimen Repository
- NCT00898235 · 10,000 participants
Collection of Samples and Clinical Data From Patients With Amyloid Diseases
- NCT00992303 · 10,000 participants
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI